- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05131204
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)
A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or Ravulizumab
The primary objective of the study is:
To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy
The secondary objectives of the study are to:
Evaluate the effect of pozelimab and cemdisiran combination treatment versus anti-C5 standard-of-care treatment (eculizumab or ravulizumab) on the following:
- Transfusion requirements and transfusion parameters
- Measures of hemolysis: LDH control, breakthrough hemolysis, and inhibition of CH50
- Hemoglobin levels
- Fatigue as assessed by Clinical Outcome Assessments (COAs)
- Health-related quality of life (HRQoL) as assessed by COAs
- Safety and tolerability
- To assess the concentrations of total pozelimab and either total eculizumab or total ravulizumab in serum and total cemdisiran and total C5 protein in plasma
- To assess the immunogenicity of pozelimab and cemdisiran
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Whittier, California, United States, 90603
- Regeneron Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Diagnosis of PNH confirmed by a history of high-sensitivity flow cytometry from prior testing
- Treated with eculizumab or ravulizumab prior to screening visit as described in the protocol Note: Biosimilars are not permitted, unless approved by the Sponsor
Key Exclusion Criteria:
- Patients with a screening LDH >1.5 × ULN who have not taken their C5 inhibitor within the labeled dose interval at the dose prior to the screening LDH assessment
- Receipt of an organ transplant, history of bone marrow transplantation or other hematologic transplant
- Body weight < 40 kilograms at screening visit
- Any use of complement inhibitor therapy other than eculizumab or ravulizumab in the 26 weeks prior to the screening visit or planned use during the study with the exception of study treatments
- Not meeting meningococcal vaccination requirements for eculizumab or ravulizumab according to the current local prescribing information (where available) and at a minimum documentation of meningococcal vaccination within 5 years prior to screening visit.
- Any contraindication for receiving Neisseria meningitidis vaccination.
- Positive for hepatitis B, and/ or hepatitis C as described in the protocol
- History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
- Participation in another interventional clinical study (except R3918-PNH-2021) or use of any experimental therapy within 30 days before screening visit or within 5 half-lives of that investigational product, whichever is greater, with the exception of eculizumab or ravulizumab.
- Patients with functional or anatomic asplenia
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pozelimab and Cemdisiran
Randomized 1:1
|
Administered per protocol
Other Names:
Administered per protocol
Other Names:
Administered per protocol
Other Names:
Administered per protocol
Other Names:
|
Experimental: Anti-C5 standard-of-care
Randomized 1:1
|
Administered per protocol
Other Names:
Administered per protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in lactate dehydrogenase (LDH)
Time Frame: From baseline to week 36
|
From baseline to week 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with transfusion avoidance
Time Frame: Day 1 through week 36
|
Patients who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values
|
Day 1 through week 36
|
Proportion of patients with transfusion avoidance
Time Frame: Week 4 through week 36
|
Patients who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values
|
Week 4 through week 36
|
Proportion of patients with breakthrough hemolysis
Time Frame: Day 1 through week 36
|
Patients with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
|
Day 1 through week 36
|
Proportion of patients with breakthrough hemolysis
Time Frame: Week 4 (day 29) through week 36
|
Patients with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
|
Week 4 (day 29) through week 36
|
Proportion of patients with hemoglobin stabilization
Time Frame: Day 1 through week 36
|
Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
|
Day 1 through week 36
|
Proportion of patients with hemoglobin stabilization
Time Frame: Week 4 (day 29) through week 36
|
Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
|
Week 4 (day 29) through week 36
|
Proportion of patients with adequate control of LDH
Time Frame: Day 1 through week 36
|
Proportion of patients with adequate control of LDH as defined in the protocol
|
Day 1 through week 36
|
Proportion of patients with adequate control of LDH
Time Frame: Week 8 (day 57) through week 36
|
Proportion of patients with adequate control of LDH as defined in the protocol
|
Week 8 (day 57) through week 36
|
Proportion of patients with normalization of LDH
Time Frame: Day 1 through week 36
|
Proportion of patients with normalization of LDH as defined in the protocol
|
Day 1 through week 36
|
Proportion of patients with normalization of LDH
Time Frame: Week 8 (day 57) through week 36
|
Proportion of patients with normalization of LDH as defined in the protocol
|
Week 8 (day 57) through week 36
|
Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale
Time Frame: From baseline to week 36
|
The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week.
This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses.
The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much).
Scores range from 0 to 52, with higher scores indicating greater fatigue.
|
From baseline to week 36
|
Change in Physical Function (PF) score on the European organization for research and treatment of cancer quality-of-Life questionnaire Core 30 Items (EORTC-QLQ-C30)
Time Frame: From baseline to week 36
|
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
|
From baseline to week 36
|
Change in global health status (GHS)/QoL scale score on the EORTC-QLQ-C30
Time Frame: From baseline to week 36
|
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties).
Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
|
From baseline to week 36
|
Rate of RBCs transfused per protocol algorithm
Time Frame: Day 1 through week 36
|
Per protocol algorithm
|
Day 1 through week 36
|
Rate of RBCs transfused per protocol algorithm
Time Frame: Week 4 through week 36
|
Per protocol algorithm
|
Week 4 through week 36
|
Number of units of RBCs transfused per protocol algorithm
Time Frame: Day 1 through week 36
|
Per protocol algorithm
|
Day 1 through week 36
|
Number of units of RBCs transfused per protocol algorithm
Time Frame: Week 4 through week 36
|
Per protocol algorithm
|
Week 4 through week 36
|
Change in hemoglobin levels
Time Frame: From baseline to week 36
|
Per protocol algorithm
|
From baseline to week 36
|
Incidence and severity of treatment emergent serious adverse events (SAEs)
Time Frame: Up to 88 weeks
|
Treatment period and safety follow up period
|
Up to 88 weeks
|
Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest
Time Frame: Up to 88 weeks
|
Treatment period and safety follow up period
|
Up to 88 weeks
|
Incidence and severity TEAEs leading to treatment discontinuation
Time Frame: Up to 88 weeks
|
Treatment period and safety follow up period
|
Up to 88 weeks
|
Change in total CH50
Time Frame: From baseline to week 36
|
From baseline to week 36
|
|
Percent change in total CH50
Time Frame: From baseline to week 36
|
From baseline to week 36
|
|
Concentration of total C5 in plasma
Time Frame: Through week 62
|
Treatment period and safety follow up period
|
Through week 62
|
Concentrations of total pozelimab in serum
Time Frame: Through week 62
|
Treatment period and safety follow up period
|
Through week 62
|
Concentrations of total cemdisiran in plasma
Time Frame: Through week 32
|
Treatment period
|
Through week 32
|
Concentrations of total eculizumab in serum
Time Frame: Through week 40
|
Treatment period
|
Through week 40
|
Concentrations of total ravulizumab in plasma
Time Frame: Through week 44
|
Treatment period
|
Through week 44
|
Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab
Time Frame: Through week 62
|
Treatment period and safety follow up period
|
Through week 62
|
Incidence of treatment emergent ADAs to cemdisiran
Time Frame: Through week 62
|
Treatment period and safety follow up period
|
Through week 62
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urological Manifestations
- Bone Marrow Diseases
- Hematologic Diseases
- Urination Disorders
- Anemia
- Proteinuria
- Anemia, Hemolytic
- Myelodysplastic Syndromes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Complement Inactivating Agents
- Eculizumab
- Ravulizumab
Other Study ID Numbers
- R3918-PNH-2022
- 2020-002761-33 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paroxysmal Nocturnal Hemoglobinuria
-
Apellis Pharmaceuticals, Inc.RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal HemoglobinuriaMalaysia, United States, Czechia, France, Netherlands, Serbia, Spain, Thailand, United Kingdom
-
Novartis PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria PNHLithuania, Japan, Czechia
-
Ra PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, New Zealand, Korea, Republic of, Italy
-
AKARI TherapeuticsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Kazakhstan, Lithuania, Sri Lanka
-
Alexion PharmaceuticalsTerminatedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Czech Republic, Italy, Poland, United Kingdom
-
AlexionActive, not recruitingParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, United States, Canada, Czechia, Germany, Sweden, Singapore, Korea, Republic of, Russian Federation, Austria, Poland, Argentina, Australia, Brazil, Estonia, Malaysia, Mexico, Thaila... and more
-
Apellis Pharmaceuticals, Inc.CompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Clinical Trials on Cemdisiran
-
Regeneron PharmaceuticalsRecruitingGeneralized Myasthenia GravisKorea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
-
Alnylam PharmaceuticalsWithdrawnAtypical Hemolytic Uremic SyndromeSweden, Moldova, Republic of, Latvia, Lithuania, Estonia, Bosnia and Herzegovina, Canada, Georgia, Macedonia, The Former Yugoslav Republic of, Serbia
-
Alnylam PharmaceuticalsTerminatedIgA Nephropathy (IgAN) | Berger Disease | Glomerulonephritis, IgACanada, Malaysia, France, Sweden, United Kingdom, Philippines, Singapore, Spain, Taiwan
-
Regeneron PharmaceuticalsCompletedParoxysmal Nocturnal HemoglobinuriaKorea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
-
Regeneron PharmaceuticalsAvailableParoxysmal Nocturnal Hemoglobinuria
-
Regeneron PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsCompletedParoxysmal Nocturnal HemoglobinuriaUnited Kingdom
-
Regeneron PharmaceuticalsRecruitingParoxysmal Nocturnal HemoglobinuriaTaiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
-
Regeneron PharmaceuticalsAlnylam PharmaceuticalsCompleted
-
Mario Negri Institute for Pharmacological ResearchAlnylam PharmaceuticalsWithdrawn